Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

MYSTERIOUS: 5 - You Need To See This

Hims & Hers launches copy of Wegovy pill, prompting legal threats from drugmaker Novo Nordisk

Telehealth company Hims & Hers is launching a cheaper, off-brand version of the blockbuster weight loss pill Wegovy

The Independent UK

The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles

Eli Lilly surges past the trillion-dollar mark as aggressive manufacturing expansion drives volume growth that eclipses rival Novo Nordisk in 2026.

MarketBeat

New weight loss drug by Pfizer shows promising results in trial

Pfizer acquired the drug’s developer following a bidding war with Novo Nordisk last year

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Novo Nordisk shares plunge on outlook warning as Mounjaro rival races ahead

Wegovy and Ozempic maker Novo Nordisk forecast plunging sales and earnings in 2026, which saw the Danish drugmaker’s shares plummet by nearly a fifth.

Evening Standard

Novo Nordisk stock sinks by 17% after bleak 2026 forecast

Shares tumbled after the company predicted a 5–13% decline in 2026 sales and operating profit, citing lower US prices and rising competition.

Euronews

Wegovy and Ozempic maker forecasts sharp drop in revenue for 2026

Novo Nordisk share price plunges after blaming lower US drug prices, patent protection issues and rising competition

The Guardian - UK

As Novo Nordisk Stock Breaks Below Key Support Levels, Should You Buy the Dip?

Novo Nordisk stock sank as management forecasts decelerating growth in 2026. But should you treat this selloff in NVO shares as a buying opportunity? Let’s find out.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Why Denmark can't use Ozempic as a trump card with the US in Greenland talks

Novo Nordisk, the Danish manufacturer of weight-loss drugs Ozempic and Wegovy, has a large market share in the US. But it's not enough to put pressure on US President Donald Trump's administration during Greenland talks, experts say.

Euronews

Commodity Volatility, Earnings and Other Key Things to Watch

Markets enter February following a volatile final trading day of January that saw investors grappling with hotter-than-expected inflation data alongside news of a new Federal Reserve chair nominee.

Barchart

Small risk of severe acute pancreatitis with weight-loss jabs, UK regulator warns

Agency updates guidance after increase in reports of condition to its yellow card scheme

The Guardian - UK

Eye-stroke, vomiting and burst colon: Lawsuits accuse weight-loss drugs of severe side effects

Thousands of patients have filed lawsuits against drug producers claiming side effects - but the companies insist their products are properly tested

The Independent UK

Layoffs are piling up, heightening worker anxiety. Here are some of the biggest job cuts recently

As layoffs pile up, workers are feeling increasingly anxious about the job market

The Independent UK

5 Stocks To Keep an Eye On in 2026, According to Experts

Healthcare, retail and finance stocks could do well in 2026. See five picks that experts say could have major upside potential. Find out more right now.

GOBankingRates

Fake weight-loss medication in tablet form could flood Britain, experts warn

Better regulation and enforcement urged before launch of oral treatments, which criminals are likely to try to exploit

The Guardian - UK

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

The New Wegovy Pill Is Already Popular. Does That Make Novo Nordisk Stock a Buy for Q1?

Novo Nordisk entered 2026 with fresh momentum after the U.S. launch of its oral Wegovy pill. Is the stock a buy now?

MarketBeat

Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All

As weight loss drugs move from injections to pills, this thematic ETF provides broad exposure for investors looking to profit from the industry’s next leg up.

The Independent UK

Generic Ozempic drugs are about to flood the market

Semaglutide’s U.S. patents keep generics out until around 2031 or 2035, maintaining Novo Nordisk’s exclusivity and high prices

The Guardian - UK

Off the Scales by Aimee Donnellan review – inside the Ozempic revolution

A fascinating deep dive into the discovery, use and implications of a revolutionary new treatment

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Federal regulators are telling drugmakers to remove label warnings about potential suicidal thoughts and behaviors from their blockbuster weight-loss drugs

MarketBeat

This ETF Is Proof That the Healthcare Rebound Is Real

Track healthcare’s 2026 setup: GLP-1 drug adoption, a valuation gap vs. tech, and why VHT offers broad exposure with low fees and dividends.

Barchart

Novo Nordisk Is Getting a Major Boost from Amazon for Its New Wegovy Pill. Does That Make NVO Stock a Buy Here?

Novo Nordisk shares inch higher as the pharma giant announces an oral Wegovy partnership with Amazon Pharmacy. Here’s why NVO stock is worth owning at current levels.

The Independent UK

Amazon starts to offer Wegovy weight loss pill to customers

The new oral Wegovy, launched this week, contains semaglutide, the same active ingredient as injectable Wegovy and Ozempic

Fortune

The 7 most overlooked CEOs in 2025—and the 5 to watch in 2026

The Yale Chief Executive Leadership Institute highlights the top performers of 2025 and the top leaders to watch in 2026.

The Independent UK

From injectables to pills: how the new Wegovy tablet will change the weight loss market forever

IN FOCUS: The launch of an oral semaglutide pill approved for weight loss represents a new frontier for GLP-1 drugs. Katie Rosseinsky looks at how the landscape is changing

International Business Times UK

Wegovy Weight-Loss Pill Hits US Market — How Much It Costs, Where to Buy It and How Effective It Really Is

Novo Nordisk's Wegovy, the first oral GLP-1 weight-loss pill, is now in 70,000+ US pharmacies, costing $5 (£4) to $10 (£7) per day.

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.